STOCK TITAN
  1. Home
  2. Sec-filings
  3. ICCM
  4. [Form 3] IceCure Medical Ltd. Initial Statement of Beneficial Ownership

IceCure Medical (ICCM) VP discloses shares, RSUs and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

IceCure Medical Ltd. executive Tel-Tzure Tlalit Bussi, VP of BD & Global Marketing, reports her initial ownership position. As of March 18, 2026, she beneficially owns 170,629 ordinary shares and restricted share units. She also holds multiple share option grants over ordinary shares at exercise prices ranging from $0.92 to $5.78, with expirations between 2029 and 2034, many of which are fully vested.

Positive

  • None.

Negative

  • None.
Insider Tel-Tzure Tlalit Bussi
Role VP, BD & Global Marketing
Type Security Shares Price Value
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Ordinary shares -- -- --
Holdings After Transaction: Share option (right to buy) — 287,898 shares (Direct); Ordinary shares — 170,629 shares (Direct)
Footnotes (14)
  1. F1. Represents (i) 19,603 ordinary shares, (ii) 68,182 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, (iii) 51,978 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 30,866 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.
  2. F2. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 50,000 options are fully vested.
  3. F3. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share.
  4. F4. The options were granted on August 30, 2020, 25% of which vested on August 30, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 29,594 options are fully vested.
  5. F5. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.
  6. F6. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022 and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,370 options are fully vested.
  7. F7. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.
  8. F8. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.
  9. F9. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
  10. F10. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 3,509 options are vested.
  11. F11. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.
  12. F12. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested.
  13. F13. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
  14. F14. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,681 options are vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does the IceCure Medical (ICCM) Form 3 filing disclose for Tel-Tzure Tlalit Bussi?
The Form 3 discloses Tel-Tzure Tlalit Bussi’s initial ownership in IceCure Medical. She is VP, BD & Global Marketing and reports beneficial ownership of 170,629 ordinary shares and restricted share units as of March 18, 2026, plus several option grants over ordinary shares.

How many IceCure Medical ordinary shares and RSUs does Tel-Tzure Tlalit Bussi report on Form 3?
She reports beneficial ownership of 170,629 ordinary shares and restricted share units. A footnote explains this represents 19,603 ordinary shares plus several RSU grants, all of which remain unvested as of March 18, 2026, with specified future vesting schedules and quarterly installments.

What share options over IceCure Medical (ICCM) stock does Tel-Tzure Tlalit Bussi hold?
She holds several share option grants over ordinary shares. These include options with exercise prices of $2.27, $1.56, $5.78, $3.64, $2.84, and $1.51 per share, each tied to specific grant dates and expirations between 2029 and 2034, many already fully vested.

Are Tel-Tzure Tlalit Bussi’s IceCure Medical options vested according to the Form 3 footnotes?
Several option grants are fully vested as of March 18, 2026, while others vest over time. Footnotes state that options granted in 2019, 2020, 2021, and early 2022 are fully vested, whereas later grants vest 25% at the first anniversary and 6.25% quarterly thereafter.

Did Tel-Tzure Tlalit Bussi buy or sell IceCure Medical shares in this Form 3 filing?
The filing does not report any explicit purchases or sales. All entries are categorized as holdings, with transaction codes left blank and the transaction summary showing no buy, sell, or exercise activity, only holding entries and unknown transaction codes for the reported positions.

What are the exercise prices and currency details for Tel-Tzure Tlalit Bussi’s IceCure options?
Exercise prices were originally set in New Israeli Shekels and converted to U.S. dollars. Footnotes state an exchange rate of NIS 3.10 to $1.00, resulting in U.S. dollar exercise prices such as $2.27, $1.56, $5.78, $3.64, $2.84, and $1.51 per share.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Tel-Tzure Tlalit Bussi
(Last)(First)(Middle)
7 HA'ESHEL ST., PO BOX 3163
(Street)
CAESAREA3079504
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP, BD & Global Marketing
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares170,629(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy) (2)03/28/2029Ordinary shares50,000$2.27(3)D
Share option (right to buy) (4)08/30/2030Ordinary shares29,594$1.56(5)D
Share option (right to buy) (6)04/28/2031Ordinary shares1,370$5.78(7)D
Share option (right to buy) (8)01/12/2032Ordinary shares80,668$3.64(9)D
Share option (right to buy) (10)03/23/2032Ordinary shares3,743$2.84(11)D
Share option (right to buy) (12)02/19/2033Ordinary shares40,705$1.51(13)D
Share option (right to buy) (14)07/02/2034Ordinary shares81,818$0.92D
Explanation of Responses:
1. Represents (i) 19,603 ordinary shares, (ii) 68,182 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, (iii) 51,978 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 30,866 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.
2. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 50,000 options are fully vested.
3. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share.
4. The options were granted on August 30, 2020, 25% of which vested on August 30, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 29,594 options are fully vested.
5. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.
6. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022 and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,370 options are fully vested.
7. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.
8. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.
9. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
10. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 3,509 options are vested.
11. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.
12. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested.
13. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
14. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,681 options are vested.
/s/ Tlalit Bussi Tel-Tzure03/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR